ArticlePharmaceutical research2026
Preclinical Evaluation of a Nanoformulated Hydrogen Sulfide-releasing Dexamethasone for Topical Treatment of Psoriasis.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeConcerns regarding local and systemic adverse effects associated with long-term use of corticosteroids has motivated the study of new therapeutic approaches for psoriasis treatment. This study evaluated the efficacy of a novel nanoformulation loaded with a hydrogen sulfide (H₂S)-releasing dexamethasone derivative (Dexa-TBZ) in an experimental psoriasis model.
methodsPsoriasis was induced with topical imiquimod, and mice were treated for 4 days with dexamethasone- (Dexa, control) or Dexa-TBZ-loaded nanoformulations. Erythema and scaling (assessed by a modified Psoriasis Area Severity Index), myeloperoxidase (MPO) activity, and spleen size were assessed for efficacy.
resultsDaily topical treatment with either Dexa or Dexa-TBZ reduced scaling and erythema, with the last most likely related to decreased inflammation, as suggested by a marked reduction in MPO activity and neutrophil infiltration. Both treatments also reduced epidermal thickening, indicating comparable local therapeutic effects. However, Dexa caused a greater reduction in circulating leukocytes and spleen size, suggesting higher systemic exposure despite topical administration. In contrast, Dexa-TBZ showed limited systemic effects.
conclusionsAlthough Dexa-TBZ did not demonstrate superior local efficacy, its lower systemic impact suggests an improved safety and tolerability profile, which may be advantageous for the long-term topical treatment of chronic conditions such as psoriasis.
Indexed as
Identifiers
42920045What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.